Treatment with the senolytics dasatinib/quercetin reduces SARS-CoV-2-related mortality in mice.
Aging Cell
; 22(3): e13771, 2023 03.
Article
em En
| MEDLINE
| ID: mdl-36704839
ABSTRACT
The enormous societal impact of the ongoing COVID-19 pandemic has been particularly harsh for some social groups, such as the elderly. Recently, it has been suggested that senescent cells could play a central role in pathogenesis by exacerbating the pro-inflammatory immune response against SARS-CoV-2. Therefore, the selective clearance of senescent cells by senolytic drugs may be useful as a therapy to ameliorate the symptoms of COVID-19 in some cases. Using the established COVID-19 murine model K18-hACE2, we demonstrated that a combination of the senolytics dasatinib and quercetin (D/Q) significantly reduced SARS-CoV-2-related mortality, delayed its onset, and reduced the number of other clinical symptoms. The increase in senescent markers that we detected in the lungs in response to SARS-CoV-2 may be related to the post-COVID-19 sequelae described to date. These results place senescent cells as central targets for the treatment of COVID-19, and make D/Q a new and promising therapeutic tool.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Quercetina
/
COVID-19
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Aging Cell
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Espanha